DDrare: Database of Drug Development for Rare Diseases

Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1) Inosine 5'-monophosphate; 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one; 11C-methylreboxetine; 13N-Ammonia; 18F-Dopa; 18F-Dopamne; AFFITOPE® PD01A + Adjuvant; AFFITOPE® PD03A + Adjuvant; AZD3241; AZD3241 100mg; AZD3241 300mg; AZILECT; AZILECT 1 mg comprimidos; Adjuvant without active component; Ammonia; Ampreloxetine; Ampreloxetine chydrochloride; Ampreloxetine hydrochloride; Angiotensin; Angiotensin-(1-7); Anti-Parkinson medication; Atomexetine; Autologous mesenchymal stem cells; Azilect; BHV-3241; BHV-4157; BIIB101; BOTULINUM TOXIN TYPE A; BQ123; Behavioral: BCI-FIT active querying; Behavioral: BCI-FIT adaptive signal modeling; Behavioral: BCI-FIT language modeling; Behavioral: BCI-FIT multi-modal access; Behavioral: Clinical characteristics of AMS patients; Behavioral: Conservative Measures for Orthostatic Hypotension; Behavioral: MOntreal Cognitive Assessment (MoCA); Blood sampling; Botulinum toxin type A; Bq123; Bydureon; CS10BR05; Captopril; Carbidopa; Carbidopa 200mg oral dose; Carbonate; DMI; DOPS; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Desipramine; Desipramine (DMI); Device: Abdominal compression; Device: Deep Brain Stimulation; Device: sham compression; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Domperidone; Droxidopa; EGCG; EGCG as putative neuroprotective agent; Emeramide; Entacapone; Entacapone 400mg oral dose; Exenatide; Exenatide Pen Injector [Bydureon]; FLUOXETINE; Fipamezole; Fipamezole hydrochloride; Fipamezole hydrochloride 30 mg oral disintegrating tablets; Fipamezole hydrochloride 60 mg oral disintegrating tablets; Fipamezole hydrochloride 90 mg oral disintegrating tablets; Fludrocortisone; Flumazenil; Fluoxetine; Fluoxétine; Flutemetamol; Flutemetamol F18; GREEN TEA LEAF; Gold; Green Tea; Green tea leaf; Homeostasis Model Assessment of insulin resistance (HOMA); Hydrogen; IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one; IVIg; Inosine; Intranasal Insulin; Intravenous immunoglobulin (IVIg); Intravesical injection of Botulinum A toxin; JP-1730/F01; JP-1730/F02; JP-1730/F03; L-Threo DOPS; LITHIUM CARBONATE; LITIO CARBONATO; Levodopa; Levodopa test; Lithium Carbonate; Lithium carbonate; Losartan; Metoprolol; Metoprolol tartrate 50 mg; Midodrine; Modal; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NT 101; Nebivolol; Nebivolol 5 mg; Nitrogen; Normal saline; Other: Abdominal compression; Other: Brain MRI (magnetic resonance imaging); Other: Sham abdominal compression; PROZAC; Procedure: Brain Magnetic Resonance Imaging (MRI); Procedure: determination of objective and subjective pain threshold; Pseudoephedrine; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; RASAGILINA MESILATO; Raclopride; Radiation: H215O PET; Radiation: PET (Positron Emission Tomography) Study; Rasagilina; Rasagiline; Rasagiline mesylate; Rifampicin; Riluzole; Rituximab; SAFINAMIDE; Safinamide; Safinamide Methanesulfonate; Safinamide methanesulfonate; Saline; Sildenafil25 mg; Sirolimus; Sirolimus 2 MG; Sunphenon EGCg; TD-9855; Tea leaf; Tllsh2910; Trimethaphan; Ubiquinol; Verdiperstat; Water; Xadago; Xeomin; [18F]FDOPA; [F-18]PBR06

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03446807 (ClinicalTrials.gov)	January 2020	20/2/2018	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy	Drug: Droxidopa;Drug: Placebo Oral Tablet	Loma Linda University	H. Lundbeck A/S	Not yet recruiting	50 Years	N/A	All	32	Phase 2	United States
2	NCT02897063 (ClinicalTrials.gov)	September 2016	7/9/2016	Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure	The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2	Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension	Drug: Droxidopa;Drug: Midodrine;Drug: Placebo	Vanderbilt University Medical Center	NULL	Recruiting	40 Years	80 Years	All	34	Phase 1	United States
3	NCT02071459 (ClinicalTrials.gov)	January 21, 2014	21/2/2014	Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA	Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo	Multiple System Atrophy	Drug: L-Threo DOPS;Drug: placebo	University Hospital, Toulouse	NULL	Completed	30 Years	80 Years	All	107	Phase 2;Phase 3	France
4	NCT00738062 (ClinicalTrials.gov)	January 2008	19/8/2008	Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)	An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension	Neurogenic Orthostatic Hypotension;Non-Diabetic Autonomic Neuropathy;Multiple System Atrophy;Dopamine Beta Hydroxylase Deficiency	Drug: Droxidopa;Drug: Placebo	Chelsea Therapeutics	NULL	Completed	18 Years	N/A	All	103	Phase 3	United States;Australia;Canada;New Zealand
5	NCT00547911 (ClinicalTrials.gov)	October 2007	19/10/2007	Augmenting Effects of L-DOPS With Carbidopa and Entacapone	L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone	Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases	Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Terminated	18 Years	N/A	All	14	Phase 1;Phase 2	United States
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00004478 (ClinicalTrials.gov)	March 1999	18/10/1999	Droxidopa in Treating Patients With Neurogenic Hypotension	Study of Droxidopa in Patients With Neurologic Hypotension	Shy-Drager Syndrome;Orthostatic Hypotension	Drug: droxidopa	Mount Sinai School of Medicine	NULL	Completed	20 Years	N/A	Both		N/A	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03446807
(ClinicalTrials.gov)

January 2020

20/2/2018

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy

Drug: Droxidopa;Drug: Placebo Oral Tablet

Loma Linda University

H. Lundbeck A/S

Not yet recruiting

50 Years

N/A

All

Phase 2

United States

NCT02897063
(ClinicalTrials.gov)

September 2016

7/9/2016

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2

Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension

Drug: Droxidopa;Drug: Midodrine;Drug: Placebo

Vanderbilt University Medical Center

NULL

Recruiting

40 Years

80 Years

All

Phase 1

United States

NCT02071459
(ClinicalTrials.gov)

January 21, 2014

21/2/2014

Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA

Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo

Multiple System Atrophy

Drug: L-Threo DOPS;Drug: placebo

University Hospital, Toulouse

NULL

Completed

30 Years

80 Years

All

107

Phase 2;Phase 3

France

NCT00738062
(ClinicalTrials.gov)

January 2008

19/8/2008

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Neurogenic Orthostatic Hypotension;Non-Diabetic Autonomic Neuropathy;Multiple System Atrophy;Dopamine Beta Hydroxylase Deficiency

Drug: Droxidopa;Drug: Placebo

Chelsea Therapeutics

NULL

Completed

18 Years

N/A

All

103

Phase 3

United States;Australia;Canada;New Zealand

NCT00547911
(ClinicalTrials.gov)

October 2007

19/10/2007

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone

Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases

Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Terminated

18 Years

N/A

All

Phase 1;Phase 2

United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00004478
(ClinicalTrials.gov)

March 1999

18/10/1999

Droxidopa in Treating Patients With Neurogenic Hypotension

Study of Droxidopa in Patients With Neurologic Hypotension

Shy-Drager Syndrome;Orthostatic Hypotension

Drug: droxidopa

Mount Sinai School of Medicine

NULL

Completed

20 Years

N/A

Both

N/A

United States